Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Holding CTSO?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.07Last Year’s EPS
-$0.12Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 1.33%
|Next Earnings Date:Mar 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with strong revenue growth, significant reductions in operating expenses, and important regulatory progress for DrugSorb ATR. However, the decline in gross margins and decreased grant revenue are notable challenges. The sentiment leans towards optimism with strategic advancements in product development and market readiness.Company Guidance
In the CytoSorbents' Q3 2024 earnings call, the company reported product sales of $8.6 million, exceeding their guidance of $8.3 million to $8.5 million and marking an 11% year-over-year growth. The product gross margins stood at 61%, slightly down from 71% the previous year, due to a planned slowdown in production and a resolved short-term manufacturing issue. Operating expenses decreased by 25%, leading to a 40% reduction in operating loss, and the cash burn was reduced to $2.7 million from $5 million in the previous quarter. CytoSorbents also highlighted their progress on the DrugSorb ATR device, with FDA and Health Canada regulatory decisions anticipated in 2025, potentially opening a $300 million initial total addressable market, expected to grow significantly. The company is targeting increased operational efficiency and margin expansion, aiming to achieve 75% to 80% product gross margins in the future.Strong Revenue Growth
Q3 2024 product sales were $8.6 million, above the previously guided range of $8.3 million to $8.5 million and representing 11% growth year-over-year.
Operating Expense Reduction
Operating expenses decreased 25% year-over-year, driving a 40% reduction in operating loss.
Regulatory Progress for DrugSorb ATR
Submitted De Novo medical device marketing application to the FDA for DrugSorb ATR, with regulatory decisions expected in 2025. The application is eligible for priority review.
Positive Clinical Data
The STAR-T trial showed reduced bleeding severity in isolated CABG population, with a favorable benefit-to-risk profile.
---
CTSO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CTSO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $0.90 | $0.74 | -17.78% |
| Aug 13, 2024 | $0.90 | $0.97 | +7.78% |
| May 09, 2024 | $0.81 | $0.91 | +12.35% |
| Mar 14, 2024 | $0.97 | $0.88 | -9.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cytosorbents Corp (CTSO) report earnings?
Cytosorbents Corp (CTSO) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Cytosorbents Corp (CTSO) earnings time?
Cytosorbents Corp (CTSO) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTSO EPS forecast?
CTSO EPS forecast for the fiscal quarter 2024 (Q4) is -$0.07.
---